Feasibility and safety of SGLT2 inhibition by empagliflozin for the preservation of pancreas function in recent-onset type 1 diabetes
Latest Information Update: 25 Feb 2020
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 24 Feb 2020 Status changed from active, no longer recruiting to completed.
- 15 Jan 2019 Planned End Date changed from 31 Mar 2019 to 30 Jun 2019.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.